素对非过敏性鼻炎的疗效:最新的系统性审查和元分析
Jiatong Wang1, Leilani Zhang2,3, Kangyang Zheng2
1Southern Medical University, Guangzhou, China. 16622356879@163.com.
Clinical reviews in allergy & immunology
|October 18, 2024
概括
素通过减少鼻腔症状来治疗非过敏性鼻炎 (NAR) 是有前途的. 这项元分析发现,与安慰剂相比,素显著改善了症状得分和响应率,这表明了对NAR的潜在新疗法.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 由于有效的治疗选择有限,非过敏性鼻炎 (NAR) 具有重大临床挑战.
- 提高鼻腔反应率是NAR的一个关键特征,表明有针对性的干预措施可能是有益的.
- 素是一种TRPV1受体激动剂,正在研究其调节鼻腔感觉通路的潜力.
研究的目的:
- 系统地审查和元分析素在治疗非过敏性鼻炎症状中的疗效.
- 评估素对全鼻症状评分 (TNSS),视觉模拟量表 (VAS) 评分和治疗反应率的影响.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 包括9项安慰剂对照研究,评估素对NAR.
- 主要结果指标包括TNSS,VAS分数和治疗响应者的比例.
主要成果:
- 分析表明,对素治疗和安慰剂治疗的TNSS和VAS得分有统计学上的显著改善.
- 在素组中观察到更高比例的治疗反应者.
- 一些研究表明物质P水平和TRPV1表达减少,尽管需要进一步研究.
结论:
- 素治疗在缓解与非过敏性鼻炎相关的症状方面表现出初步的有效性.
- 这些发现表明,素是NAR的有前途的治疗剂.
- 需要使用标准化方法进行更大,更严格的设计试验,以确认疗效并确定临床效用.
相关概念视频
Allergic Reactions
33.9K
Overview
33.9K
Dose-Response Relationship: Potency and Efficacy
7.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.5K
Upper Respiratory Drugs: Decongestants
1.3K
Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in...
Most decongestants are readily available over-the-counter in...
1.3K


